The Treatment of Older Patients With Multiple Myeloma
C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma.
C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma. This interview took place at the 2013 American Society of Hematology (ASH) Meeting.
Clinical Pearls
-Every year in the U.S., 10,000 people under the age of 70 and 10,000 people over the age of 70 are diagnosed with multiple myeloma
-Younger patients typically experience better outcomes while older patients do not see much improvement
@TargetedOncUsing newer therapy strategies, my projection is that#MultipleMyelomapts 70+ yrs will have 2-3x better survival within 5 yrs
Ola Landgren, M.D. (@DrOlaLandgren)April 9, 2014
-Now that older patients are being treated with new drugs, they​ are seeing an improvement in survival
Care Teams Ease Inpatient/Outpatient Transitions in Multiple Myeloma
December 5th 2024Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance challenges, and multiple providers, highlighting the need for comprehensive care plans to ensure optimal outcomes.
Read More
FDA Accepts BLA for Belantamab Mafodotin Combinations in R/R Multiple Myeloma
November 25th 2024The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported by DREAMM-7 and DREAMM-8 data.
Read More
